Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2019-05-29 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
第二届董事会第三十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of 贝达药业股份有限公司 (Betta Pharmaceuticals Co., Ltd.). It details the convening of the board meeting, attendance, and the approval of several proposals related to the company's 2018 stock option incentive plan, including adjustments to exercise prices, cancellation of certain stock options, and confirmation of exercisable stock options. The document includes voting results and mentions related disclosures filed on the China Securities Regulatory Commission's designated information disclosure website. The content focuses on board decisions and management actions rather than financial results, audit opinions, or shareholder voting outcomes. It is not a full annual or interim report, nor is it a call transcript or earnings release. It is not a proxy solicitation or voting results announcement. The document is a board/management information announcement about decisions made by the board, specifically regarding stock option plans and related corporate governance matters. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is 2223 characters, which is consistent with a detailed announcement but not a full report.
2019-05-29 Chinese
关于注销公司2018年（第一期）股票期权激励计划部分已授期权的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from a company regarding the cancellation of part of its 2018 stock option incentive plan. It details the background of the stock option plan, adjustments to the number of options granted, reasons for cancellation of some options, and the impact on the company. It includes board and supervisory committee approvals, independent director opinions, and legal opinions. The document is an official announcement about changes to the company's stock option incentive plan, specifically the cancellation of some granted options, rather than a full report or financial statement. It does not contain financial statements or detailed financial analysis but focuses on corporate governance and management decisions related to stock options. This fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories. The document length is 3236 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2019-05-29 Chinese
关于调整公司2018年（第一期）股票期权激励计划首次授予股票期权行权价格的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding an adjustment to the exercise price of stock options granted under its 2018 stock option incentive plan. It details the board and supervisory committee meetings, shareholder approvals, and legal opinions related to the adjustment. The document does not contain financial statements or comprehensive financial data but rather focuses on a specific corporate action related to stock option pricing adjustments. This type of announcement fits best under the category of Capital/Financing Update (CAP), as it relates to changes in the company's capital structure through stock option adjustments. The document length is 3346 characters, which is consistent with an announcement rather than a full report. Therefore, the appropriate classification is CAP with high confidence.
2019-05-29 Chinese
独立董事关于第二届董事会第三十三次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters discussed at the company's 33rd board meeting of the second session. It focuses on stock option incentive plans, adjustments to exercise prices, cancellation of granted options, and approval of the first exercise period. The content is related to board-level decisions and opinions rather than financial results, audit reports, or regulatory announcements. There is no indication of a full annual or interim report, earnings release, or other financial filings. The document is a formal opinion from independent directors on board matters, which fits the category of Board/Management Information (MANG). The document length is short (1663 characters), and it is not an announcement of a report but a substantive opinion document. Therefore, the classification is MANG with high confidence.
2019-05-29 Chinese
第二届监事会第二十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a supervisory board meeting of Betta Pharmaceuticals Co., Ltd. It details the meeting's convening, attendance, and voting results on stock option incentive plan adjustments and cancellations. The content focuses on governance decisions and internal supervisory board approvals rather than financial results, audit opinions, or regulatory filings. It is not a full annual or interim report, nor an earnings release or capital update. The document is a meeting resolution announcement related to board/supervisory decisions, which fits best under Board/Management Information (MANG). The document length is 2032 characters, indicating it is a concise announcement rather than a full report. Therefore, the classification is MANG with high confidence.
2019-05-29 Chinese
关于2018年（第一期）股票期权激励计划首次授予股票期权第一个行权期可行权的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding the first exercise period of a stock option incentive plan granted in 2018. It details the approval process by the board and supervisory committees, the number of stock options granted, adjustments to the exercise price, cancellation of some options, and confirmation that exercise conditions have been met. It also includes legal opinions and committee approvals. The document is not a full annual or interim financial report, nor is it a regulatory filing or a simple announcement of a report. It is a detailed disclosure about stock option incentive plan execution and related corporate governance matters. This fits best under the category of Capital/Financing Update (CAP), as it relates to stock option grants and exercise, which affect the company's capital structure and financing activities.
2019-05-29 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.